FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Tags >> Synagis   AstraZeneca
Syndicate content

motavizumab News

Most Popular motavizumab Story

Motavizumab failure shifts spotlight to RSV vaccines

The news this week that AstraZeneca ($AZN) is writing off its big motavizumab program for RSV has shifted the spotlight to a slate of earlier stage compounds as well as vaccines. The Wall Street Read more...

motavizumab Press Releases

  • MedImmune Receives FDA Complete Response Letter on Motavizumab

Latest Headlines